Phase II Clinical Trial Evaluating Cabozantinib and Pembrolizumab in Metastatic Pancreatic Cancer

Grants and Contracts Details

StatusActive
Effective start/end date4/29/216/7/23

Funding

  • Exelixis Inc.: $108,759.00